Microrna-34a promotes hepatic stellate cell activation via targeting ACSL1

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 3008-3015

  Yan, Gangli ^a,b   Li, Binbin ^a   Xin, Xuan ^a,c   Xu, Midie ^a   Ji, Guoqing ^d,e   Yu, Hongyu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b The People's Liberation Army 161 Hospital   (China)

^c Central Hospital of Jinan   (China)

^d FUDAN UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

Hepatic stellate cells; Liver cirrhosis; MicroRNAs

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; DESMIN; LONG CHAIN FATTY ACID COENZYME A LIGASE; MICRORNA 34A; 3' UNTRANSLATED REGION; ACTIN; ASCL1 PROTEIN, HUMAN; ASCL1 PROTEIN, RAT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DIMETHYLNITROSAMINE; MICRORNA; MIRN34 MICRORNA, HUMAN; MIRN34 MICRORNA, RAT;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENETIC REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIVER FIBROSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; WESTERN BLOTTING; 3' UNTRANSLATED REGION; ANIMAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEK293 CELL LINE; HEPATIC STELLATE CELL; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

3' UNTRANSLATED REGIONS; ACTINS; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DIMETHYLNITROSAMINE; GENE EXPRESSION REGULATION; GENE SILENCING; HEK293 CELLS; HEPATIC STELLATE CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; MALE; MICRORNAS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84943626324     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.894000     Document Type: Article

References (36)

1. Alcolado R, Iredale P: Pathogenesis of liver fibrosis. Studies, 1997; 50: 51
2. Friedman SL: Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol, 2010; 7: 425-36
3. Wang XW, Heegaard NH, Ørum H: MicroRNAs in liver disease. Gastroenterology, 2012; 142: 1431-43
4. Lu P, Liu H, Yin H, Yang L: Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Am J Case Rep, 2011; 17: 248-56
5. Qu Y, Chen W-H, Zong L et al: 18alpha-Glycyrrhizin induces apoptosis and suppresses activation of rat hepatic stellate cells. Med Sci Monit Basic Res, 2011; 18: 24-32
6. Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem, 2000; 275: 2247-50
7. Wu J, Zern MA: Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol, 2000; 35: 665-72
8. Veidal SS, Nielsen MJ, Leeming DJ, Karsdal MA: Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model. BMC Res Notes, 2012; 5: 686
9. Mòdol T, Brice N, Ruiz de Galarreta M et al: Fibronectin peptides as potential regulators of hepatic fibrosis through apoptosis of hepatic stellate cells. J Cell Physiol, 2015; 230: 546-53
10. Haybaeck J, Zeller N, Heikenwalder M: The parallel universe: microRNAs and their role in chronic hepatitis, liver tissue damage and hepatocarcinogenesis. Swiss Med Wkly, 2011; 141: w13287
11. Vettori S, Gay S, Distler O: Role of microRNAs in fibrosis. Open Rheumatol J, 2012; 6: 130-39
12. Zhang J-W, Li Y, Zeng X-C et al: miR-630 overexpression in hepatocellular carcinoma tissues is positively correlated with alpha-fetoprotein. Med Sci Monit, 2015; 21: 667-73
13. Li WQ, Chen C, Xu MD et al: The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J, 2011; 278: 1522-32
14. Parkes HA, Preston E, Wilks D et al: Overexpression of acyl-CoA synthetase-1 increases lipid deposition in hepatic (HepG2) cells and rodent liver in vivo. Am J Physiol Endocrinol Metab, 2006; 291: E737-44
15. Soupene E, Kuypers FA: Mammalian long-chain acyl-CoA synthetases. Exp Biol Med, 2008; 233: 507-21
16. Ellis JM, Frahm JL, Li LO, Coleman RA: Acyl-coenzyme A synthetases in metabolic control. Curr Opin Lipidol, 2010; 21: 212-17
17. Kojima-Yuasa A, Ohkita T, Yukami K et al: Involvement of intracellular glutathione in zinc deficiency-induced activation of hepatic stellate cells. Chem Biol Interact, 2003; 146: 89-99
18. Kawada N, Tran-Thi TA, Klein H, Decker K: The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Eur J Biochem, 1993; 213: 815-23
19. Ji J, Zhang J, Huang G et al: Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett, 2009; 583: 759-66
20. Chen K, Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet, 2007; 8: 93-103
21. Tang G, Shen X, Lv K et al: Different normalization strategies might cause inconsistent variation in circulating microRNAs in patients with hepatocellular carcinoma. Med Sci Monit, 2015; 21: 617-24
22. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell, 2009; 136: 215-33
23. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005; 120: 15-20
24. Friedman RC, Farh KK-H, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 2009; 19: 92-105
25. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J et al: Identification of tissue- specific microRNAs from mouse. Curr Biol, 2002; 12: 735-39
26. Trang P, Weidhaas J, Slack F: MicroRNAs as potential cancer therapeutics. Oncogene, 2008; 27: S52-57
27. Li C, Feng Y, Coukos G, Zhang L: Therapeutic microRNA strategies in human cancer. AAPS J, 2009; 11: 747-57
28. Fasanaro P, Greco S, Ivan M et al: microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther, 2010; 125: 92-104
29. Sandoval A, Fraisl P, Arias-Barrau E et al: Fatty acid transport and activation and the expression patterns of genes involved in fatty acid trafficking. Arch Biochem Biophys, 2008; 477: 363-71
30. Li X, Gonzalez O, Shen X et al: Endothelial acyl-CoA synthetase 1 is not required for inflammatory and apoptotic effects of a saturated fatty acidrich environment. Arterioscler Thromb Vasc Biol, 2013; 33: 232-40
31. Umlauf E, Csaszar E, Moertelmaier M et al: Association of stomatin with lipid bodies. J Biol Chem, 2004; 279: 23699-709
32. Kang M-J, Fujino T, Sasano H et al: A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Proc Natl Acad Sci USA, 1997; 94: 2880-84
33. Ellis JM, Mentock SM, DePetrillo MA et al: Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy. Mol Cell Biol, 2011; 31: 1252-62
34. Li LO, Ellis JM, Paich HA et al: Liver-specific loss of long chain acyl-CoA synthetase- 1 decreases triacylglycerol synthesis and b-oxidation and alters phospholipid fatty acid composition. J Biol Chem, 2009; 284: 27816-26
35. Cui M, Wang Y, Sun B et al: MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem Biophys Res Commun, 2014; 444: 270-75
36. Tang Y, Chen A: Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids. Endocrinology, 2010; 151: 4168-77